These use mercaptan MSN (MSN-SH) to detect low molecular weight proteins and distinguish between patients with benign prostatic hyperplasia and those with PCa with elevated PSA levels (Vidaurre-Agut et al., 2019). The gene discussed is KLK3; the disease is posterior cortical atrophy.